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Abstract
Background: Acquired immunodeficiency syndrome (AIDS), which is caused by the human immunodeficiency
virus (HIV), is an immunosuppressive disease that results in life-threatening opportunistic infections. The general
problems in current therapy include the constant emergence of drug-resistant HIV strains, adverse side effects and
the unavailability of treatments in developing countries. Natural products from herbs with the abilities to inhibit
HIV-1 life cycle at different stages, have served as excellent sources of new anti-HIV-1 drugs. In this study, we
aimed to investigate the anti-HIV-1 activity of aqueous dandelion extract.
Methods: The pseudotyped HIV-1 virus has been utilized to explore the anti-HIV-1 activity of dandelion, the level
of HIV-1 replication was assessed by the percentage of GFP-positive cells. The inhibitory effect of the dandelion
extract on reverse transcriptase activity was assessed by the reverse transcriptase assay kit.
Results: Compared to control values obtained from cells infected without treatment, the level of HIV-1 replication
and reverse transcriptase activity were decreased in a dose-dependent manner. The data suggest that dandelion
extract has a potent inhibitory activity against HIV-1 replication and reverse transcriptase activity. The identification
of HIV-1 antiviral compounds from Taraxacum officinale should be pursued.
Conclusions: The dandelion extract showed strong activity against HIV-1 RT and inhibited both the HIV-1 vector
and the hybrid-MoMuLV/MoMuSV retrovirus replication. These findings provide additional support for the potential
therapeutic efficacy of Taraxacum officinale. Extracts from this plant may be regarded as another starting point for
the development of an antiretroviral therapy with fewer side effects.
Background
Human immunodeficiency virus type 1 (HIV-1) is the
causative agent of acquired immunodeficiency syndrome
(AIDS). This disease represents a huge concern for glo-
bal public health. Currently, there is no effective vaccine
for HIV-1 [1]; thus, prevention and antiviral drugs are
the only option to decrease morbidity and mortality in
HIV-1-infected individuals. Several classes of antiretro-
viral drugs have been developed targeting viral proteins
at different stages of the HIV-1 life cycle or host factors.
Highly active antiretroviral therapy (HAART) [2], which
typically utilizes a protease inhibitor in combination
w i t han u c l e o s i d ea n d / o rn o nnucleoside reverse tran-
scriptase inhibitor, is commonly used to treat HIV-1
infected patients. The general problems in current HIV
therapy are the constant emergence of drug-resistant
HIV strains, adverse side effects and the unavailability of
treatments in developing countries. Thus, developing
cost-effective, highly-specific and antiresistant drugs are
in urgent need.
Natural products, especially those derived from plants,
have long been recognized as excellent sources of new
anti-HIV-1 drugs. Some of them exhibit inhibitory activ-
ity against several HIV-1 processes, including viral entry,
reverse transcription, replication, integration, virus
maturation, and virion budding. Some of these com-
pounds have been clinically tested, with favorable results
[3-8]. Limonoid and nomilin, which are isolated from
the seed of Citrus bergamia, inhibit both HTLV-1 and
HIV-1 reverse transcriptase (RT) activities [9]. Betulinic
acid, a triterpenoid isolated from the methyl alcohol
extract of the leaves of Syzigium claviflorum,a n dn o v e l
betulinic acid derivatives have been used as potent anti-
HIV agents [10,11], and new mechanisms for these
* Correspondence: bgao2004@gmail.com
1CAS Key Laboratory of Pathogenic Microbiology and Immunology (CASPMI),
Institute of Microbiology, Chinese Academy of Sciences, Beijing, PR China
Full list of author information is available at the end of the article
Han et al. BMC Complementary and Alternative Medicine 2011, 11:112
http://www.biomedcentral.com/1472-6882/11/112
© 2011 Han et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.compounds have been identified [12-14]. These com-
pounds have become a new class of anti-HIV drugs.
Phase I and II studies have reported that single oral
dose of bevirimat, derived from a betulinic acid-like
compound, was well tolerated and demonstrated a dose-
dependent reduction in viral load. Derivative IC9564
also competed with gp120/CD4 complexes for binding
to chemokine receptors, thus acting as an entry inhibitor
that can potently inhibit a broad spectrum of primary
HIV-1 isolates by targeting the V3 loop of gp120. Simi-
larly, Trigonostema xyphophylloides from Euphorbia-
ceae and Vatica astrotricha from Dipterocarpaceae have
been shown to act as HIV-1 entry inhibitors. These
compounds likely inhibit HIV-1 replication by blocking
the interaction between gp120 and CD4/CCR5 or gp120
and CD4/CXCR4. Petroleum ether from Rhus chinensis
does not inhibit HIV-1 recombinant RT or HIV-1 entry
into host cells, but may target new sites of HIV-1 repli-
cation [15]. Shikonin from the dried root of Lithosper-
mum erythrorhizon is a pan-chemokine receptor
inhibitor [16]. Lipophosphoglycan (LPG) from Leishma-
nia donovani has been shown to inhibit the early stage
of the HIV-1 life cycle by influencing the membrane
fluidity of target cells and diminishing both the virus-
cell and cell-to-cell fusion processes initiated by HIV-1
[17].
Taraxacum officinale, also known as the common
dandelion, has been shown to have heat clearing and
detoxifying effects in addition to the ability to eliminate
stagnation, remove stasis and induce diuresis for treating
strangurtia. This plant is one of the common antiviral
agents used in traditional Chinese medicines. Histori-
cally, it has been used to treat numerous diseases, ran-
ging from infectious diseases; tumors of the breast,
uterus and lung; kidney disease; digestive diseases; and
diabetes. Some of the traditional applications of dande-
lion extract are supported by pharmacological investiga-
tion. Modern pharmacological research suggests this
plant has broad-spectrum antibacterial [18], anti-fungal
[19], antiviral, antidiabetic, choleretic, antirheumatic,
anti-inflammatory [20,21], hepatoprotective [22], diuretic
[23], and tumor apoptosis-inducing properties [24-26].
However, the antiretroviral properties of this plant have
not been examined until recently.
Virus cell-based fluorescence assay using pseudotype
particles is an efficient and cost-effective screening sys-
tem and has been used for primary screening of novel
agents against HIV-1 [27-30]. Pseudotyped viruses pro-
duced in this system can mimic most stages of the HIV-
1 life cycle, including viral protein production, assembly,
release, maturation, entry, integration and replication
without producing replication-competent viruses. This
approach has the potential to identify inhibitors against
multiple viral and cellular functions essential for HIV
replication [30]. The level of HIV-1 replication has been
assessed by the expression of reporter genes represented
by the percentage of GFP-positive cells.
This study aimed to investigate the in vitro inhibitory
effects of aqueous dandelion extract (DWE) on HIV-1
replication by utilizing VSV-G pseudotyped viruses to
infect non-CD4 cells. Reverse transcriptase assay kit was
used to detect inhibitory effect on RT enzyme activity of
dandelion. These results suggest that dandelion extract
has a potent inhibitory activity against HIV-1 replication
and RT activity. The further investigation should include
the identification of the active components in the dan-
delion extract.
Methods
Cell lines and cell culture
A l lc e l ll i n e s ,t h em o u s ef i b r o b l a s tc e l ll i n e( N I H / 3 T 3 ) ,
293T human renal epithelial cell, RetroPackPT67 packa-
ging cells and Phoenix Eco packaging cells were pur-
chased from ATCC (Rockville, MD, USA) and grown in
Dulbecco’s modified eagle medium (DMEM; GIBCO,
USA) supplemented with 10% fetal bovine serum (FBS;
Gibco, USA), 100 IU/ml penicillin and 100 μg/ml strep-
tomycin. The cells were incubated in a humidified envir-
onment with 5% CO2 at 37°C. Peripheral mononuclear
blood cells (PBMCs) were purified using Ficoll density
gradient centrifugation from healthy donors supplied by
the Beijing Blood Bank. PBMCs were resuspended and
cultured in RPMI-1640 medium supplemented with 10%
FBS and 100 U/ml recombinant human IL-2 overnight
before they were used in the cytotoxicity assay. Based
on an informed consent, this project was approved by
the Biomedical Research Ethics Committee of CAS Key
Laboratory of Pathogenic Microbiology and Immunology
(NO.CASPMI009).
Retroviral vector and packaging cell construction
pLNCX2 contains elements derived from the Moloney
murine leukemia virus (MoMuLV) and the Moloney
murine sarcoma virus (MoMuSV) and is designed for
retroviral gene delivery. The pLNCX2 retroviral vector
(donated by professor Huang) was chosen to insert
enhanced green fluorescent protein (EGFP). The EGFP




and the fragment was inserted into the pLNCX2 retro-
viral vector at the XhoI/Sal I restriction enzyme site.
The Phoenix Eco packaging cells were transfected with
pLNCX2-EGFP using calcium phosphate-based transfec-
tion. The retroviral supernatant was collected 48 h post-
transfection, filtered through a 0.45 μm filter and stored
at -80°C for subsequent use. RetroPack PT67 cells were
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supernatant in the presence of 8 μg/ml polybrene
(Sigma Co., St Louis, MO) using centifugation at 1200
xg at 32°C for 90 min. Six hours after infection, the
supernatant was removed and the cells were incubated
i nt h ec o m p l e t em e d i u m .T h ee x p r e s s i o no ft h e
p L N C X 2 - E G F Pr e t r o v i r a lv e c tor was verified by selec-
tion with 100 μg/ml G418 (GIBCO, USA).
The pLNCX2-EGFP-transfected RetroPack PT67
packaging cells encoding the EGFP genes were used as a
stable EGFP virus-producing cell line and cultured in
DMEM supplemented with 10% FBS. Retaining one
p l a t ef o rt h ec o n t i n u a t i o no f the culture, the remaining
cells were plated at 60-80% confluence in the desired
number of culture vessels. Viral supernatants could then
be harvested in 24 h intervals until the cells were no
longer viable. Once the virus was harvested, all cells
were discarded.
Production of pseudotyped virus and transduction
To produce single-cycle infectious virons, VSV-G pseu-
dotyped HIV-1 vector stocks were prepared, concen-
trated and titered as described previously [31]. The
pLL3.7 plasmid (6 μg; Invitrogen, USA), belonging to
the third generation of lentivirus vector system based on
HIV-1, was co-transfected with pLP1 (Invitrogen, USA),
pLP2 (Invitrogen, USA) and pLP/VSVG (Invitrogen,
USA) into 293T cells using calcium phosphate-based
transfection. After transfection (48 to 72 h), the virus-
containing supernatants were harvested, passed through
a0 . 4 5μm filter and frozen in aliquots at -80°C until
use. NIH/3T3 cells were placed in each well of a six-
well plate with 2 ml DMEM containing 10% FBS. The
next day, the media was replaced with 2 ml of virus
supernatants containing 8 μg/ml of polybrene at a mul-
tiplicity of infection (MOI) of 1 in the presence or
absence of DWE. Zidovudine (AZT) and Herba Artemi-
siae Scopariae were used as positive control and nega-
tive control respectively. The cells were infected by
spinoculation in a centrifuge at 1, 200 xg for 90 min at
32°C and incubated at 37°C overnight, followed by a
change to fresh medium.
Plant material
Samples of the entire plant of Taraxacum officinale
(dried) and Herba Artemisiae Scopariae (dried) were
purchased at Fenlinlvzhou medicinal store in Beijing,
China in December 2010 and authenticated by ph.D
Wei Li, Institute of Microbiology, Chinese Academy of
Sciences. The voucher specimen of these plant materials
were deposited in the CAS Key Laboratory of Patho-
genic Microbiology and Immunology (CASPMI), Insti-
tute of Microbiology, Chinese Academy of Sciences.
Quantification of the inhibitory effect of DWE to HIV-1 RT
The effect of DWE on HIV-1 RT activity was evaluated
with the reverse transcriptase assay, coloremetric kit
(Version 13.0, Roche, USA). The assay was performed
according to the manufacture’s instructions by transfer-
ring 20 μl of recombinant HIV-1 RT and 20 μl reaction
buffer to microfuge tubes containing different concen-
trations of DWE (2 mg/ml, 1 mg/ml, 0.75 mg/ml, 0.5
mg/ml, 0.25 mg/ml, 0.125 mg/ml) and diluted with lysis
buffer. 2.5 μM AZT was used as a positive control, lysis
buffer without HIV-1 RT was used as one negative con-
trol (control 1), lysis buffer with HIV-1 RT but no DWE
was used as another negative control (control 2). After 1
h incubation at 37°C, the samples were transfered into
microplate modules for 1 h incubation again at 37°C.
The plate was rinsed 5 times with 250 μlo fw a s h i n g
buffer and buffer was completely removed before adding
200 μl of anti-DIG-POD working dilution. A further 1 h
incubation at 37°C followed by washing 5 times with
washing buffer. 200 μl ABTS substrate solution was
added per well and incubated at room temperature until
color development is sufficient for photometric detec-
tion (10-30 min). The absorbance was read on a micro-
plate reader at 405 nm and a reference wavelength of
490 nm. The assay was carried out in triplicate and
repeated three times. Results were analyzed using the
formula:
% relative inhibition = (RTcontrol2 − RTcontrol 1) − (RTsample − RTcontrol1)
× 100/ RTcontrol2 − RTcontrol1
Preparation of extracts
10 g of the dried whole plant of Taraxacum officinale
and Herba Artemisiae Scopariae were respectively
soaked in water for 0.5 h at room temperature. Hot
water extractions were performed at 100°C in three
batches: 200 ml for 3 h, 150 ml for 2 h, 100 ml for 1 h.
The mixtures were then pooled together and filtered to
remove the particulate matter, concentrated to 100 ml,
filtered through a 0.22 μm syringe filter and lyophilized,
yielding light yellow power.
Cell survival assay
The cytotoxicity of DWE to NIH/3T3 cells was assessed
using a CCK-8 assay (Cell Counting Kit, Dojindo
Laboratories, Kumamoto, Japan). NIH3T3 cells were
seeded in 96-well plates at an initial density of 3 × 10
3
cells/well in 100 μl of culture medium. After 24 h of
incubation, the cells were treated in the presence or
absence of the different compounds at different concen-
trations ranging from 8 mg/ml to 0.25 mg/ml and 100
μMt o0 . 0 0 0 1μM of AZT. The medium was removed,
and the cells were washed twice with fresh media. Next,
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Cell Counting Kit-8 reagent was added to each well and
incubated for an additional 4 h. After incubation, the via-
bility of the NIH/3T3 cells was assayed with CCK-8
using a 96-well plate reader (DG5032, Huadong, Nanjing,
China) at 450 nm. Untreated cells were served as the
negative control, and wells containing the Cell Counting
Kit-8 reagent and no cells were used as the blank control.
Cytotoxicity was assessed by the cell survival rate. The
absorbance reading from each well was used to calculate
the cell survival rate. Survival rate (%) = optical density
(OD) of the treated cells -OD of blank control/OD of
negative control-OD of blank control × 100.
The cytotoxicity of DWE in human PBMCs was deter-
mined using the trypan blue exclusion method. Briefly,
PBMCs were cultured at 1.3 × 10
6 cells/ml in a 24-well
plate supplemented with 100 IU/ml IL-2 and exposed to
increasing concentrations of DWE for 24 h. PBMCs
without DWE treatment were used as a control. The
cells were stained with 0.2% trypan blue dye, and the
total cells and viable cells were counted under a light
microscope.
Flow cytometry, fluorescence microscopy analysis and
image acquisition
NIH3T3 cells were harvested using a trypsin/EDTA
solution, washed with ice-cold PBS three times and
resuspended in PBS to a final concentration of 10
6 cells/
ml. Virus infection was measured in the absence or pre-
sence of increasing concentrations of DWE. The percen-
tage of EGFP-positive cells was used to calculate the
infection efficiency by flow cytometry using Guava Easy-
Cyte (Guava Technologies, USA). All FACS data were
analyzed using FlowJo software (Tree Star, Ashland OR).
Images were acquired on a ZEISS Axiovert 200 M
microscope (Zeiss, Vienna, Austria) with a 40 x/0.55NA
objective. The microscope and image acquisition were
controlled by AxioVision software. For GFP observation,
we used blue light excitation. Image processing, such as
the clipping of images, was first performed in Power-
Point and then converted to TIFFs.
High performance liquid chromatography(HPLC)
200 mg freeze-dried aqueous extract powder was dis-
solved in 2 ml milli-Q water, and filtered through a 0.22
μm syringe filter before analysis. HPLC separation was
conducted by a Shimadzu CTO-15C system equipped
with a binary high pressure gradient pump, UV/Vis
detector SPD-15C. Peak areas were calculated with a LC
solution 15C software. Gradient elution was performed
using two solvents consisting of A (0.1% (v/v) TFA in
H2O) and B ((0.1%(v/v) TFA in acetonitrile). Step gradi-
ent is from 5% to 70% of B over 40 min. Total chroma-
tography duration was 40 min. The flow-rate of mobile
phase was 1 ml/min. Injection volume was 25 μl. The
detection wavelengths were set at 254 and 323 nm, and
column temperature was room temperature. The caffeic
acid and chlorogenic acid purchased from Sigma (USA)
were used as the reference standards for quantitative
assay. The concentrations of components present in
DWE were identified by comparing chromatographic
peaks with the retention time of individual standards.
Statistical analysis
Data are presented as mean ± SD. The data were statis-
tically evaluated using a one-way ANOVA to compare
differences between the groups. A p-value of < 0.05 was
considered to be significant. The IC50 values were cal-
culated using GraphPad Prism programme.
Results
Production of the VSV-G pseudotyped HIV-1 virus and
10A1 pseudotyped pLNCX2-EGFP vector
We chose EGFP as a reporter gene because its expres-
sion can be easily monitored. As illustrated in Figure
1A, expression of EGFP served as an indicator of viral
replication. pLNCX2-EGFP was generated by inserting
the EGFP gene downstream from the CMV promoter.
Virus-producing RetroPack PT67 cells were established
through a ping-pong method, which uses the virus from
the Eco packaging cell line to infect RetroPack PT67
cells. Finally, a stable pLNCX2-EGFP transfected Retro-
Pack PT67 cell line was selected using G418. As shown
in Figure 1B, high level of EGFP was observed in all Ret-
roPack PT67 cells. Our experimental design was
showned in Figure 1C.
In vitro effects of Taraxacum officinale extracts on cell
viability
The dried whole plant of T. officinale was extracted with
hot water, yielding DWE (17% w/w). It was important to
assess whether the compounds were toxic to exclude a
non-specific antiretroviral effect. We determined the effects
of the extracts on cell survival in the absence of HIV-1
infection to establish a non-toxic working concentration of
the DWE. The cytotoxicity of DWE in NIH/3T3 cells was
evaluated using a CCK-8 assay. The experiments were
repeated three times for six different concentrations (0.25
mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml).
For concentrations up to 2 mg/ml, no significant cytotoxic
effects were found (Figure 2A). The concentration of 2 mg/
ml was chosen to carry out the subsequent studies based
on cell viability and morphological observations.
Taraxacum officinale extract has no toxicity in human PBMCs
The cytotoxicity of DWE on human PBMCs was tested
by evaluating cellular viability and was confirmed using
the trypan blue test following exposure to increasing
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shown in Figure 2B, PBMC viability was not decreased
at concentrations up to 8 mg/ml. Compared to
untreated PBMCs, both the number of total cells and
the number of viable cells were significantly increased
after treatment with DWE at a concentration of 0.0625
mg/ml (p < 0.05). These data indicate that DWE exhi-
bits no toxicity on human PBMCs and served as a nutri-
ent or stimulator at a low concentration.
Inhibitory activity of Taraxacum officinale extract on HIV-1
replication
When compared to control values obtained from
infected cells that were not treated with the plant
extracts, DWE showed inhibitory activity that increased
in a concentration-dependent manner. This was seen as
a decrease of GFP-positive counts in a dose-dependent
manner (see graphs in Figure 3). AZT, a reverse tran-
scriptase inhibitor, was used as a positive control. As
s h o w ni nF i g u r e4 A ,t h e5 0 %i n hibitory concentration
(IC50)o fA Z Tf o rH I V - 1w a s0 . 2 9μM, which is in
accordance with previously published data. We used the
previously determined non-toxic concentration of 2 mg/
ml as the starting testing point for DWE. The maximum
inhibitory effect (98%) was obtained with 2 mg/ml, and
the IC50 of DWE was 0.64 mg/ml, As a negative control,
the extract from Herba Artemisiae Scopariae showed
much weaker inhibitory activity with an IC50 of 1.255
mg/ml when compared to the activities of Taraxacum
officinale observed. Next, we determined whether DWE
was similarly effective in the inhibition of another retro-
virus unrelated to HIV-1, the 10A1-pseudotyped hybrid-
MoMuLV/MoMuSV retrovirus. We found DWE also to
be effective for this virus. The maximum inhibitory
effect (73%) was obtained with 2 mg/ml, and the IC50 of
DWE was 0.23 mg/ml (Figure 4B). The similar ability of
DWE to inhibit the replicationo ft w ou n r e l a t e dr e t r o -
viruses suggests that dandelion extract may target a fac-
tor that is broadly required for retroviral replication.
Inhibitory effects of Taraxacum officinale extract on HIV-1
RT activity
Anti-HIV-1 activity of the aqueous extract of dandelion
was further investigated using RT assay, which is a
Figure 1 Construction of retroviral and HIV-1 replication reporter vector system. (A) The pLNCX2 -EGFP vector, constructed by inserting
the EGFP gene into the multiple cloning site of the pLNCX2 plasmid, a retroviral vector contains elements derived from Moloney murine
leukemia virus (MoMuLV) and Moloney murine sarcoma virus (MoMuSV). The HIV-1 based lentiviral vector pLL3.7 is commercially available, and
EGFP is driven by the CMV promoter. (B) The development of stable RetroPackPT67 packaging cells encoding the EGFP genes, which was used
as the EGFP virus-producing cell line. (C) Outline of the anti-HIV-1 activity assay for DWE.
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mined after treatments in the presence or absence
(untreated control) of different concentrations of DWE.
Inhibition of DWE to the HIV-1 RT enzyme was
evaluated based on their percent inhibition compared to
a sample that does not contain DWE. As showned in
Figure 4C, DWE showed potent inhibitory effect at 2
mg/ml (94.89%) with an IC50 of 0.87 mg/ml compared
Figure 2 Cytotoxicity assay for different cells cultured with different concentrations of DWE. (A) NIH/3T3 cell survival curves from the
CCK-8 assay. The negative control was untreated cells, and the blank control contained the Cell Counting Kit-8 reagent and no cells. The curve
represents the average of three independent experiments with SD bars. (B) PBMCs were incubated at 37°C in 5% CO2 overnight in media
supplemented with IL-2 at a concentration of 100 IU/ml. The cells were then exposed to the DWE for 24 h, and aliquots of cells were stained
with trypan blue dye to determine the total numbers of cells as well as viable cells. PBMC cells, cultured in the absence of DWE were used as
control. These data represent three independent experiments.
Figure 3 Fluorescence micrograph of GFP proteins in infected cells treated with DWE. NIH/3T3 cells expressing EGFP following infection
with VSV-G pseudotyped HIV-1 virus. (A) NIH/3T3 cells infected with the pLL3.7 lentivirus without DWE (untreated). Figures show NIH/3T3 cells
infected with the pLL3.7 lentivirus in the presence of DWE at a concentration of (B) 0.25 mg/ml (C) 0.5 mg/ml (D) 1 mg/ml. In the upper panels,
cells are visualized under normal light, while in the lower panels, the same cells are visualized by fluorescent microscope.
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tory activities were dose dependent.
Discussion
The present study demonstrates for the first time that
DWE displays inhibitory effect on HIV-1 replication and
RT activitiy. It has been reported that extracts contain-
ing marked concentrations of chlorogenic acid inhibited
HIV reverse transcriptase [32,33]. Dandelion are rich in
phenolic compounds, in particular chlorogenic acid, caf-
feic acid, various flavonoid glycosides such as luteolin 7-
O-glucoside, luteolin and others, however, as shown in
Figure 5, HPLC analysis of two Compositae plant spe-
cies showed that Herba Artemisiae Scopariae extract,
which contain higher contents of chlorogenic acid and
caffeic acid than those in DWE (212-fold and 7-fold,
respectively), showed milder inhibitory activity on HIV-
1 replication. Since DWE are mixture of components,
there is a possibility that the anti-HIV-1 compound may
be novel. The isolation of active components against
HIV-1 RT from Taraxacum officinale is now in pro-
gress. The activity exhibited by DWE gives some evi-
dence to validate their effect against HIV-1.
Cell-based assays are one of the high-throughput
screening used to identify new inhibitors that target on
different steps in the HIV-1 life cycle. Single-cycle infec-
tious pseudotyping of HIV-1 using the envelope glyco-
protein of the vesicular stomatitis virus (VSV-G) can
mimic some behaviors of the wild-type viruses [34].
High-titer stocks of the single-cycle infectious virus can
be generated from producer cells. In addition, using the
single-cycle infectious viruses in HIV-1 reporter virus
Figure 4 Inhibitory effects of DWE on HIV-1 and another retrovirus. Figure A and B shows the effects of DWE on HIV-1 and another
retrovirus pLNCX2 -EGFP replication. Gene expression of NIH/3T3 cells were infected with two pseudotyped retroviruses for 12 h and treated
with different concentrations of DWE. Different concentrations of AZT (from 0 μMt o1 0μM) and aqueous Herba Artemisiae Scopariae extract
(HASWE) were used as positive control and negative control respectively. (A) NIH/3T3 cells infected with VSV-G pseudotyped HIV-1; (B) NIH/3T3
cells infected with MoMuLV/MoMuSV hybrid retrovirus; (C) Percentage of inhibition of HIV-1 RT by DWE. 2.5 μM AZT was used as the positive
control with 98% inhibitory rate while lysis buffer with no HIV-1 RT was used as one negative control, lysis buffer with HIV-1 RT but no DWE was
used as another negative control. The data represent the mean ± SD of triplicate experiments
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with replication-competent HIV-1. Taking these into
account, experts emphasize the importance of developing
cell-based screening systems for the rapid identification
of novel anti-HIV agents [35-38]. Moreover, to explore
the different mechanism of anti-HIV-1 activity, choosing
an appropriate cell line is a critical step. Human CD4+
Jurkat cells are commonly used in screening anti-HIV-1
drugs [6,39,40], but other reports have indicated dande-
lion root extract shows a selective induction of apoptosis
through the activation of caspase-8 in human leukemia
cells (Jurkat) [26]. In our study, we used VSV-G pseudo-
typed HIV-1, which has a different entry pathway from
wild-type HIV-1 [34], and a non-CD4 cell line. The assay
used here targeted HIV-1 replication, a post-entry event.
A deletion in the U3 region results in the loss of promo-
ter activity following reverse transcription and integration.
The only promoter that dictates the transcription of a
reporter gene is the internal promoter CMV. Thus, the
expression of GFP protein is a reliable indicator of HIV-1
replication [41]. It is also important to distinguish specific
antiretroviral activity from non-specific inhibitor effects
or DWE-mediated cytotoxicity. We combined cytotoxicity
data with antiretroviral testing to solve this issue. DWE
has been studied in mice, and it was reported that the
administration of DWE at 1 g/kg/day for 4 weeks did not
produce adverse effects [22]. We also observed that DWE
had no cytotoxic effect on primary PBMCs.
Conclusions
In conclusion, the dandelion extract showed strong
activity against HIV-1 RT and inhibited both the HIV-1
vector and the hybrid-MoMuLV/MoMuSV retrovirus
replication. These findings provide additional pharmaco-
logical information on the potential therapeutic efficacy
of Taraxacum officinale. This could represent another
starting point for the development of an anti-retroviral
therapy with fewer side effects.
This preliminary finding suggested to isolate bioactive
compound from biologically active extracts for further
study. Components activity tests of the plants extracts
would be performed for anti-HIV-1 activities. It is desir-
able to determine the effects of DWE on wild-type HIV-
1 as well as to try to isolate active constituents.
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